Skip to main content
Premium Trial:

Request an Annual Quote

Epistem Aims to Raise £2.8M

NEW YORK (GenomeWeb News) – Epistem Holdings said that it plans to raise £2.8 million ($4.4 million) through the placement of 793,398 new ordinary shares at 350 pence each.

The offering price is a slight discount to the trading price of around 362.5 pence before the placement was announced Friday. The Manchester, UK-based firm said that it has conditionally placed the shares with unnamed existing and new institutional investors.

Epistem plans to use the proceeds from the placement to accelerate development of its Genedrive point-of-care device for molecular diagnostics, pharmacogenomics, biodefense, and forensic applications. The firm said the system, which it is developing for bacterial, viral, fungal, and gene mutations, is in clinical trials across a number of diagnostic areas.

Epistem also has biomarker deals with several pharmaceutical firms including Sanofi-Aventis, Novartis, AstraZeneca, and Johnson & Johnson.

The Scan

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.

Sequencing Study Leads to Vaccine Target in Bacteria Behind Neonatal Meningitis

Researchers eBioMedicine track down potential vaccine targets with transposon sequencing on mutant bacteria causing neonatal meningitis in mouse models of the disease.

Multiple Myeloma Progression Influenced by Immune Microenvironment Expression

Researchers in NPJ Genomic Medicine compare RNA sequencing profiles of 102,207 individual cells in bone marrow samples from 18 individuals with rapid or non-progressing multiple myeloma.

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.